China Tracker - Details for China Nuokang Bio-Pharma (NKBP)

Warning: fopen(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/fixyou/public_html/tracker_details.php on line 58

Warning: fopen( failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/fixyou/public_html/tracker_details.php on line 58

Warning: fgetcsv() expects parameter 1 to be resource, boolean given in /home/fixyou/public_html/tracker_details.php on line 60

Warning: fclose() expects parameter 1 to be resource, boolean given in /home/fixyou/public_html/tracker_details.php on line 61
 China Nuokang Bio-Pharma
Shares Outstanding (MRQ): 19.89 mill
New Shares / Dilution (TTM): 3.58 mill21.91% 
Cash (MRQ): 29.06 mill0.00%
Account Receivables (MRQ): 20.08 mill0.00%
Account Receivables (Q/Q): -2.92 mill  
Long-Term Debt (MRQ): 5.30 mill0.00%
Revenue Growth (Q/Q): -4.65% 
Revenue Growth (Y/Y): -4.25%
Net Income Growth (Q/Q): -96.98% 
Net Income Growth (Y/Y): -98.65%
EPS Growth (Y/Y): -98.90%
Net Margin (Q/Q): 0.3% (11.0%)-10.70% 
Net Margin (Y/Y): 0.3% (24.9%)-24.50% 
EPS | P/E (2 MRQ Projection): $0.140.00 
Price/Sales (2 MRQ Projection): 0.00
Price/Book (MRQ): 0.00 
Auditor: Ernst & Young
* operating cash flow data not (yet) included
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2010-10-31): $0.550.00 
 Basic Facts and History (show more)
Reporting Type: Foreign Company (20-F Filings) 
Going Public: IPO on 2009-12-10 
IPO Price: $9.00 (-100.00% since IPO)

 Business Outlook

We recognize that commercialization of our new products progresses slower than expected but would like to highlight Baquting's continued strong performance. Our sales volume rose this quarter to 3.9 million units from 3.2 million units in the previous quarter and 3.8 million units in the prior year period. Furthermore, we have seen Reptilase, one of our key competitors, gradually recede from the market as it has been over a year since the expiration of its import license and its inventory in China is depleting. Concurrently, we are proud to note that our own market share has risen again to 40% as of June 2011. Looking forward, we are confident that Baquting will retain a leading market share position and will continue to grow.

As we have said before, Baquting is our main source of revenue. Our pipeline products have the potential to become significant revenue contributors. The commercialization process of these new products is dynamic and complicated. We have made considerable progress in the provincial bidding process and will diligently market these new products to hospitals and physicians to drive market recognition. For the full year of 2011, we are confident that Baquting will perform in line with the prior year and are cautiously optimistic regarding revenue contribution from new products.

(Source: Globe Newswire, 2011-08-25)

We continue to expect 15% top-line growth for the full year of 2011, driven by revenue growth in the second half of 2011. Our direct sales team reorganization and continued product launch efforts add certain near-term volatility but we are confident that the second half of 2011 will demonstrate significant growth as we begin to realize the benefits of our new structure and revenue contribution from our product launches grow.

(Source: Globe Newswire, 2011-05-25)

With two new products lined up in the coming year, 2011 will be an exciting time for Nuokang. At the same time, it is difficult to assess the market acceptance of our new product launches. We are confident, however, that our mature Baquting franchise will maintain its steady growth momentum. We will provide a more specific update once we are better able to assess the near term market potential of our pipeline products.

(Source: Globe Newswire, 2011-03-16)

    see all Business Outlook notes

Warning: Division by zero in /home/fixyou/public_html/tracker_details.php on line 652
 Analyst Coverage (show more)

NKBP is currently followed by 2 analysts. Both give the stock a positive rating. The average price target is 8.25.

    see all Analyst Ratings
Healthcare & Drugs
READ: Score Cards Explained
DETAILS: Safety/Risk Model for NKBP
Current Price:  n/a
F10k Day (2009-12-10): -100.00%$8.67
2009 Close: -100.00%$7.85
2010 Close: -100.00%$3.79
2011 Close: -100.00%$2.76
High (2012-09-27): -100.00%$5.40
Low (2012-04-05): -100.00%$3.38
Market Capitalization: n/a
Total Shares: 19.89 mill
Float: n/a
Avg Volume: 15.20 k
Short Interest: 4.70 k
Short Ratio: 0.08%0.3 d
Last Quarter: 2010-12-31
Revenue (MRQ): 12.02 mill
Net Income (MRQ): 0.04 mill
all financial data provided without warranty